Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Neutropenia Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Neutropenia Overview | 10 | 1 |
| Neutropenia Therapeutics under Development by Companies | 11 | 3 |
| Neutropenia Pipeline Products Glance | 14 | 4 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Unknown Stage Products | 17 | 1 |
| Neutropenia Products under Development by Companies | 18 | 1 |
| Neutropenia Companies Involved in Therapeutics Development | 19 | 16 |
| Apotex Inc. | 19 | 1 |
| BeyondSpring Pharmaceuticals, Inc. | 20 | 1 |
| Biogenomics Limited | 21 | 1 |
| Cellerant Therapeutics, Inc. | 22 | 1 |
| Cleveland BioLabs, Inc. | 23 | 1 |
| Coherus BioSciences, Inc. | 24 | 1 |
| Dr. Reddy's Laboratories Limited | 25 | 1 |
| Eurofarma Laboratorios S.A. | 26 | 1 |
| Ligand Pharmaceuticals, Inc. | 27 | 1 |
| NAL Pharmaceuticals Ltd. | 28 | 1 |
| Prolong Pharmaceuticals, LLC | 29 | 1 |
| Richter Gedeon Nyrt. | 30 | 1 |
| Sandoz International GmbH | 31 | 1 |
| Therapeutic Proteins International, LLC | 32 | 1 |
| Toko Pharmaceutical Industries Co., Ltd. | 33 | 1 |
| USV Pvt Ltd | 34 | 1 |
| Neutropenia Therapeutics Assessment | 35 | 11 |
| Assessment by Monotherapy Products | 35 | 1 |
| Assessment by Target | 36 | 3 |
| Assessment by Mechanism of Action | 39 | 3 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 35 |
| ACN-8337 Drug Profile | 46 | 1 |
| CBLB-612 Drug Profile | 47 | 2 |
| EC-18 Drug Profile | 49 | 1 |
| filgrastim Drug Profile | 50 | 1 |
| filgrastim Drug Profile | 51 | 1 |
| filgrastim Drug Profile | 52 | 1 |
| filgrastim Drug Profile | 53 | 1 |
| filgrastim Drug Profile | 54 | 1 |
| LG-7455 Drug Profile | 55 | 1 |
| pegfilgrastim Drug Profile | 56 | 1 |
| pegfilgrastim Drug Profile | 57 | 1 |
| pegfilgrastim Drug Profile | 58 | 1 |
| pegfilgrastim Drug Profile | 59 | 1 |
| pegfilgrastim Drug Profile | 60 | 1 |
| pegfilgrastim Drug Profile | 61 | 1 |
| pegfilgrastim Drug Profile | 62 | 2 |
| pegfilgrastim Drug Profile | 64 | 1 |
| pegfilgrastim Drug Profile | 65 | 1 |
| pegfilgrastim Drug Profile | 66 | 1 |
| pegfilgrastim Drug Profile | 67 | 1 |
| pegfilgrastim Drug Profile | 68 | 1 |
| pegfilgrastim (recombinant) Drug Profile | 69 | 1 |
| plinabulin Drug Profile | 70 | 4 |
| romyelocel-L Drug Profile | 74 | 3 |
| ST-7 Drug Profile | 77 | 1 |
| tamibarotene Drug Profile | 78 | 3 |
| Neutropenia Dormant Projects | 81 | 2 |
| Neutropenia Product Development Milestones | 83 | 9 |
| Featured News &Press Releases | 83 | 1 |
| Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case | 83 | 1 |
| Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case | 83 | 1 |
| Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study | 84 | 1 |
| May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication | 85 | 1 |
| Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets | 85 | 1 |
| Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim | 86 | 1 |
| Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study | 87 | 1 |
| Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 | 87 | 1 |
| Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program | 87 | 1 |
| Dec 08, 2015: EMA started the evaluation of Richter s marketing authorisation application for biosimilar pegfilgrastim | 88 | 1 |
| Dec 07, 2015: Phase III Data Shows Sandoz Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product | 88 | 1 |
| Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA | 89 | 1 |
| Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study | 90 | 1 |
| Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study | 91 | 1 |
| Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil) | 91 | 1 |
| Appendix | 92 | 2 |
| Methodology | 92 | 1 |
| Coverage | 92 | 1 |
| Secondary Research | 92 | 1 |
| Primary Research | 92 | 1 |
| Expert Panel Validation | 92 | 1 |
| Contact Us | 92 | 1 |
| Disclaimer | 93 | 1 |